Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study.

Guggulsterone 1, the active principle of guggulipid, has been used in ethnic medicine for thousands of years for its antinflammatory and antilipidemic activities. The activities of 1 are apparently mediated by its interaction with an array of nuclear receptors, including endocrine steroid receptors and metabolic lipid receptors. Although relatively weak, the activity at the metabolic farnesoid X receptor (FXR) is particularly intriguing, as 1 is, so far, the only antagonist known for this receptor, with a peculiar ability of gene selective modulation. We report here a systematic study aimed at identifying the potential binding pocket of 1 at FXR. Although 1 could be docked into the canonical binding site, we identified a novel, so far undescribed binding pocket, localized near the loop region between helix 1 and helix 2. This novel binding pocket may explain some of the peculiar characteristics of 1 when acting at FXR.

[1]  J. Dallongeville,et al.  Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. , 2002, The Journal of clinical investigation.

[2]  T. Willson,et al.  6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.

[3]  N. Blomberg,et al.  Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family , 2001 .

[4]  J. Chiang,et al.  Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of heaptocyte nuclear factor 4alpha in mediating bile acid repression. , 2001, The Journal of biological chemistry.

[5]  J. Lehmann,et al.  Bile acids: natural ligands for an orphan nuclear receptor. , 1999, Science.

[6]  D. Rader,et al.  Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. , 2003, JAMA.

[7]  M. Makishima,et al.  The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. , 2001, Gastroenterology.

[8]  Satyavati Gv.  Gum guggul (Commiphora mukul)--the success story of an ancient insight leading to a modern discovery. , 1988 .

[9]  R. Blevins,et al.  Farnesoid X Receptor Activates Transcription of the Phospholipid Pump MDR3* , 2003, Journal of Biological Chemistry.

[10]  D. Moore,et al.  The Farnesoid X-activated Receptor Mediates Bile Acid Activation of Phospholipid Transfer Protein Gene Expression* , 2000, The Journal of Biological Chemistry.

[11]  T. Willson,et al.  Identification of a Bile Acid-responsive Element in the Human Ileal Bile Acid-binding Protein Gene , 1999, The Journal of Biological Chemistry.

[12]  J. Chiang,et al.  Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7alpha-hydroxylase gene. , 2003, Biochemical and biophysical research communications.

[13]  G. Costantino,et al.  Molecular dynamics simulation of the ligand binding domain of farnesoid X receptor. Insights into helix-12 stability and coactivator peptide stabilization in response to agonist binding. , 2005, Journal of medicinal chemistry.

[14]  M. Bowman,et al.  A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. , 2003, Molecular cell.

[15]  D. Russell.  The enzymes, regulation, and genetics of bile acid synthesis. , 2003, Annual review of biochemistry.

[16]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[17]  B. Paigen,et al.  The hypolipidemic natural product Commiphora mukul and its component guggulsterone inhibit oxidative modification of LDL. , 2004, Atherosclerosis.

[18]  K. Houck,et al.  The Hypolipidemic Natural Product Guggulsterone Is a Promiscuous Steroid Receptor Ligand , 2005, Molecular Pharmacology.

[19]  G. Costantino,et al.  Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR). , 2003, Bioorganic & medicinal chemistry letters.

[20]  L. Moore,et al.  A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. , 2000, Molecular cell.

[21]  J. Chiang,et al.  Farnesoid X Receptor Responds to Bile Acids and Represses Cholesterol 7α-Hydroxylase Gene (CYP7A1) Transcription* , 2000, The Journal of Biological Chemistry.

[22]  Millard H. Lambert,et al.  Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα , 2002, Nature.

[23]  S. Wright,et al.  Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets. , 2004, DNA and cell biology.

[24]  Roberto Pellicciari,et al.  Structural basis for bile acid binding and activation of the nuclear receptor FXR. , 2003, Molecular cell.

[25]  T. Willson,et al.  Chemical genomics: Functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism , 2001, Medicinal research reviews.

[26]  Ram B. Singh,et al.  Hypolipidemic and antioxidant effects of commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia , 1994, Cardiovascular Drugs and Therapy.

[27]  M. Makishima,et al.  Identification of a nuclear receptor for bile acids. , 1999, Science.

[28]  K. Bramlett,et al.  Correlation of farnesoid X receptor coactivator recruitment and cholesterol 7alpha-hydroxylase gene repression by bile acids. , 2000, Molecular genetics and metabolism.

[29]  Paul T Tarr,et al.  Regulation of Multidrug Resistance-associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-activated Receptor, and Constitutive Androstane Receptor* , 2002, The Journal of Biological Chemistry.

[30]  Jasmine Chen,et al.  Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. , 1999, Molecular cell.

[31]  F. Gonzalez,et al.  Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. , 2003, Gastroenterology.

[32]  L. Moore,et al.  Identification of a chemical tool for the orphan nuclear receptor FXR. , 2000, Journal of medicinal chemistry.

[33]  T. A. Kerr,et al.  Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. , 2000, Molecular cell.

[34]  A. Morelli,et al.  The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. , 2004, Gastroenterology.

[35]  M. Makishima,et al.  Human Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor/Bile Acid Receptor* , 2001, The Journal of Biological Chemistry.

[36]  X. Hu,et al.  The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. , 2002, Molecular endocrinology.

[37]  R. Blevins,et al.  Human Kininogen Gene Is Transactivated by the Farnesoid X Receptor* , 2003, Journal of Biological Chemistry.

[38]  Sandor Vajda,et al.  Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping. , 2005, Biochemistry.

[39]  D. Mangelsdorf,et al.  A Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR , 2002, Science.

[40]  F. Gonzalez,et al.  Guggulsterone: an old approach to a new problem , 2002, Trends in Endocrinology & Metabolism.

[41]  T. Willson,et al.  Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. , 2001, Molecular endocrinology.

[42]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.